Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.

Park, Yeon Hee; Shin, Hyun-Tae; Jung, Hae Hyun; Choi, Yoon-La; Ahn, TaeJin; Park, Kyunghee; Lee, Aeri; Do, In-Gu; Kim, Ji-Yeon; Ahn, Jin Seok; Park, Woong-Yang; Im, Young-Hyuck

Park, Yeon Hee; Shin, Hyun-Tae; Jung, Hae Hyun; Choi, Yoon-La; Ahn, TaeJin; Park, Kyunghee; Lee, Aeri; Do, In-Gu; Kim, Ji-Yeon; Ahn, Jin Seok; Park, Woong-Yang; Im, Young-Hyuck.

Afiliación

Park YH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Shin HT; Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jung HH; Samsung Genomic Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Choi YL; Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ahn T; Samsung Genomic Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Park K; Samsung Genomic Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee A; Samsung Genomic Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Do IG; Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea.
Kim JY; Center of Companion Diagnostics, Innovative Cancer Medicine Institute, Samsung Medical Center, Seoul, Korea.
Ahn JS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Park WY; Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Im YH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Oncotarget ; 6(31): 32027-38, 2015 Oct 13.

Article en En | MEDLINE | ID: mdl-26397225

Asunto(s)

Biomarcadores de Tumor/genética; Neoplasias de la Mama/genética; Resistencia a Antineoplásicos/genética; Secuenciación de Nucleótidos de Alto Rendimiento/métodos; Mutación/genética; Receptor ErbB-2/genética; Adulto; Neoplasias de la Mama/metabolismo; Neoplasias de la Mama/secundario; Femenino; Estudios de Seguimiento; Humanos; Persona de Mediana Edad; Clasificación del Tumor; Estadificación de Neoplasias; Pronóstico; Estudios Prospectivos; ARN Mensajero/genética; Reacción en Cadena en Tiempo Real de la Polimerasa; Receptores de Estrógenos/metabolismo; Receptores de Progesterona/metabolismo; Reacción en Cadena de la Polimerasa de Transcriptasa Inversa

Palabras clave

HER pathway; HER2 mutation; next generation sequencing (NGS); refractory metastatic breast cancer; targeted sequencing

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Biomarcadores de Tumor / Receptor ErbB-2 / Resistencia a Antineoplásicos / Secuenciación de Nucleótidos de Alto Rendimiento / Mutación Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: Oncotarget Año: 2015 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google